NGM 282

Drug Profile

NGM 282

Alternative Names: NGM-282

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Cholesterol 7 alpha hydroxylase inhibitors; Fibroblast growth factor receptor modulators; Type 1 fibroblast growth factor receptor modulators; Type 4 fibroblast growth factor receptor modulators; Type-2 fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; Type 2 diabetes mellitus
  • Phase I/II Constipation

Most Recent Events

  • 20 Oct 2017 Interim efficacy and adverse events data from a clinical trial in Non-alcoholic steatohepatitis presented at the The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 20 Oct 2017 NGM Biopharmaceuticals initiates enrolment in the clinical trial for Non-alcoholic steatohepatitis in USA before October 2017
  • 19 Oct 2017 NGM Biopharmaceuticals initiates a phase II expansion trial for Non-alcoholic steatohepatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top